Details of the Drug

General Information of Drug (ID: DM1N62C)

• Drug Name: Quetiapine
• Synonyms: quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760

Indication

Disease Entry	ICD 11	Status	REF
Anorexia nervosa cachexia	6B80	Approved	[1]
Bipolar depression	N.A.	Approved	[1]
Bipolar disorder	6A60	Approved	[1]
Bipolar I disorder	N.A.	Approved	[1]
Delirium	N.A.	Approved	[1]
Major depressive disorder	6A70.3	Approved	[1]
Methamphetamine dependence	6C46.2	Approved	[1]
Schizoaffective disorder	6A21	Approved	[1]
Schizophrenia	6A20	Approved	[2]
Alcohol dependence	6C40.2	Phase 3	[3]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 383.5
  Logarithm of the Partition Coefficient (xlogp); 2.1
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-4 h []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 90% []
  Clearance: The clearance of drug is 101.04 +/- 39.11 L/h [5]
  Elimination: 73% of a dose was detected in the urine, and about 20% in the feces [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 7 hours [6]
  Metabolism: The drug is metabolized via the liver [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 34.6791 micromolar/kg/day [8]
  Vd: The volume of distribution (Vd) of drug is 10 +/- 4 L/kg [9]
  Water Solubility: The ability of drug to dissolve in water is measured as 94 mg/mL [4]
• Chemical Identifiers:
  Formula: C21H25N3O2S
  IUPAC Name: 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol
  Canonical SMILES: C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
  InChI: InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
  InChIKey: URKOMYMAXPYINW-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5002
  ChEBI ID: CHEBI:8707
  CAS Number: 111974-69-7
  DrugBank ID: DB01224
  TTD ID: D0H7KF
  VARIDT ID: DR00855
  INTEDE ID: DR1376
  ACDINA ID: D00575
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[10]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Solute carrier family 22 member 23 (SLC22A23)	DTMJK12	S22AN_HUMAN	Substrate	[11]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[14]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[14]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[15]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[14]

Molecular Expression Atlas of This Drug

• The Studied Disease: Anorexia nervosa cachexia
• ICD Disease Classification: 6B80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	3.65E-02	0.11	0.57
Dopamine D2 receptor (D2R)	DTT	DRD2	9.83E-01	6.16E-03	0.03
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.24E-01	-4.12E-01	-4.68E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.00E-02	-1.09E-02	-7.37E-02
Solute carrier family 22 member 23 (SLC22A23)	DTP	SLC22A23	3.45E-02	1.11E-01	5.53E-01
Solute carrier family 22 member 23 (SLC22A23)	DTP	SLC22A23	5.90E-01	3.60E-02	1.16E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	6.74E-01	5.99E-02	7.30E-02
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	3.51E-01	1.59E-01	2.09E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.79E-03	1.32E-01	7.85E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	1.82E-01	-1.71E-02	-9.86E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.01E-02	6.73E-02	3.36E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.91E-04	1.41E-01	6.14E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.13E-01	4.03E-02	2.50E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.21E-02	8.17E-02	4.35E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Quetiapine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Aripiprazole.	Schizophrenia [6A20]	[16]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Paliperidone.	Schizophrenia [6A20]	[17]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Molindone.	Schizophrenia [6A20]	[16]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Thiothixene.	Schizophrenia [6A20]	[16]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Amisulpride.	Schizophrenia [6A20]	[18]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Asenapine.	Schizophrenia [6A20]	[17]

Coadministration of a Drug Treating the Disease Different from Quetiapine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Quetiapine caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[19]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[20]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Midostaurin.	Acute myeloid leukaemia [2A60]	[17]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[21]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Quetiapine and Oliceridine.	Acute pain [MG31]	[22]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[23]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[23]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Ivabradine.	Angina pectoris [BA40]	[24]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Bepridil.	Angina pectoris [BA40]	[17]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Dronedarone.	Angina pectoris [BA40]	[17]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Quetiapine and Amyl nitrite.	Angina pectoris [BA40]	[25]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[26]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Posaconazole.	Aspergillosis [1F20]	[27]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Levalbuterol.	Asthma [CA23]	[28]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Pirbuterol.	Asthma [CA23]	[29]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[17]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Quetiapine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[27]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Retigabine.	Behcet disease [4A62]	[17]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Cariprazine.	Bipolar disorder [6A60]	[16]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Quetiapine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[19]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Eribulin.	Breast cancer [2C60-2C6Y]	[17]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lapatinib.	Breast cancer [2C60-2C6Y]	[17]
Tucatinib	DMBESUA	Major	Decreased metabolism of Quetiapine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Bosutinib.	Breast cancer [2C60-2C6Y]	[17]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Quetiapine when combined with Acetylcholine.	Cataract [9B10]	[30]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[31]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[32]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[32]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[32]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Quetiapine and Dihydrocodeine.	Chronic pain [MG30]	[33]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Sevoflurane.	Corneal disease [9A76-9A78]	[17]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Probucol.	Coronary atherosclerosis [BA80]	[17]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Pasireotide.	Cushing syndrome [5A70]	[17]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Osilodrostat.	Cushing syndrome [5A70]	[17]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Quetiapine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[34]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Quetiapine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[27]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Quetiapine and Cyclandelate.	Dementia [6D80-6D8Z]	[25]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Quetiapine and OPC-34712.	Depression [6A70-6A7Z]	[16]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Clomipramine.	Depression [6A70-6A7Z]	[17]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Mepenzolate.	Digestive system disease [DE2Z]	[16]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Quetiapine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[35]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Quetiapine and Deutetrabenazine.	Dystonic disorder [8A02]	[36]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Ingrezza.	Dystonic disorder [8A02]	[17]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Quetiapine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Quetiapine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Quetiapine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Quetiapine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Quetiapine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[19]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Solifenacin.	Functional bladder disorder [GC50]	[17]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[17]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Quetiapine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[27]
Telaprevir	DMMRV29	Major	Decreased metabolism of Quetiapine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[27]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Quetiapine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Quetiapine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Quetiapine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Quetiapine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Quetiapine and Penbutolol.	Hypertension [BA00-BA04]	[25]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Quetiapine and Nebivolol.	Hypertension [BA00-BA04]	[25]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Quetiapine and Levamlodipine.	Hypertension [BA00-BA04]	[25]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Quetiapine and TAK-491.	Hypertension [BA00-BA04]	[25]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Quetiapine and Hydralazine.	Hypertension [BA00-BA04]	[25]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Quetiapine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[25]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[16]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Quetiapine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[19]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Quetiapine and ITI-007.	Insomnia [7A00-7A0Z]	[16]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Quetiapine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[17]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[17]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Quetiapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[24]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Crizotinib.	Lung cancer [2C25]	[37]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Quetiapine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Osimertinib.	Lung cancer [2C25]	[38]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Selpercatinib.	Lung cancer [2C25]	[24]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Hydroxychloroquine.	Malaria [1F40-1F45]	[39]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[17]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Quetiapine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[27]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Vemurafenib.	Melanoma [2C30]	[17]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and LGX818.	Melanoma [2C30]	[17]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Quetiapine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[24]
Danazol	DML8KTN	Moderate	Decreased metabolism of Quetiapine caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[27]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Quetiapine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[40]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Quetiapine and Lasmiditan.	Migraine [8A80]	[41]
Exjade	DMHPRWG	Moderate	Increased metabolism of Quetiapine caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[19]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Quetiapine and Flibanserin.	Mood disorder [6A60-6E23]	[42]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Panobinostat.	Multiple myeloma [2A83]	[43]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Siponimod.	Multiple sclerosis [8A40]	[19]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Fingolimod.	Multiple sclerosis [8A40]	[17]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Ozanimod.	Multiple sclerosis [8A40]	[44]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Romidepsin.	Mycosis fungoides [2B01]	[17]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Quetiapine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[27]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[17]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[17]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Phenindamine.	Nasopharyngitis [CA00]	[16]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Quetiapine and Metoclopramide.	Nausea/vomiting [MD90]	[45]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Quetiapine and Lorcaserin.	Obesity [5B80-5B81]	[46]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Quetiapine and Polythiazide.	Oedema [MG29]	[25]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[24]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lofexidine.	Opioid use disorder [6C43]	[17]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Quetiapine caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[19]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Quetiapine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[27]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Triclabendazole.	Parasitic worm infestation [1F90]	[17]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Quetiapine when combined with Opicapone.	Parkinsonism [8A00]	[47]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Pimavanserin.	Parkinsonism [8A00]	[17]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Quetiapine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Methylscopolamine.	Peptic ulcer [DA61]	[16]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[49]
Lefamulin	DME6G97	Major	Decreased metabolism of Quetiapine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[50]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Quetiapine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[27]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Degarelix.	Prostate cancer [2C82]	[24]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and ABIRATERONE.	Prostate cancer [2C82]	[24]
Enzalutamide	DMGL19D	Major	Increased metabolism of Quetiapine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[19]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Relugolix.	Prostate cancer [2C82]	[24]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Quetiapine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[51]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Quetiapine when combined with Neupro.	Restless legs syndrome [7A80]	[47]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Quetiapine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[19]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Quetiapine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[27]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Quetiapine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[24]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Quetiapine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
Armodafinil	DMGB035	Minor	Increased metabolism of Quetiapine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[52]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Quetiapine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[17]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[17]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[17]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Quetiapine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[53]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lenvatinib.	Thyroid cancer [2D10]	[17]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Cabozantinib.	Thyroid cancer [2D10]	[24]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Quetiapine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[19]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[17]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[16]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Hydrazine yellow	E00409	164825	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Quetiapine 25 mg tablet	25 mg	Oral Tablet	Oral
Quetiapine 100 mg tablet	100 mg	Oral Tablet	Oral
Quetiapine 400 mg tablet	400 mg	Oral Tablet	Oral
Quetiapine 200 mg tablet	200 mg	Oral Tablet	Oral
Quetiapine 300 mg tablet	300 mg	Oral Tablet	Oral
Quetiapine 50 mg tablet	50 mg	Oral Tablet	Oral
Quetiapine 50 mg tablet	50 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 200 mg tablet	200 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 300 mg tablet	300 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 150 mg tablet	150 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 400 mg tablet	400 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 150 mg tablet	150 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Quetiapine FDA Label
• [2] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [3] ClinicalTrials.gov (NCT02362412) Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes. U.S. National Institutes ofHealth.
• [4] BDDCS applied to over 900 drugs
• [5] Huang X, Zhang S, Ma Y, Yang H, He C, Tian R, Mei H, Liu L, Zhang B: Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles. Drug Des Devel Ther. 2018 Dec 31;13:255-264. doi: 10.2147/DDDT.S182965. eCollection 2019.
• [6] Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):25-35. doi: 10.9758/cpn.2015.13.1.25.
• [7] Takahiro M, Haruo I, Toshihiko, I: Identification of Gemfibrozil Metabolites, Produced as Positional Isomers in Human Liver Microsomes, by On-line Analyses Using Liquid Chromatography/Mass Spectrometry and Liquid Chromatography/Nuclear Magnetic Resonance Spectroscopy J. Mass Spectrom. Soc. Jpn.. 2004 Jun 6;52(5):277-283.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Quetiapine fumarate fda label
• [10] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [11] Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012 Apr;12(2):165-72.
• [12] Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
• [13] Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
• [14] A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
• [15] Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014 Jan;24(1):35-42.
• [16] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [17] Canadian Pharmacists Association.
• [18] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [19] Cerner Multum, Inc. "Australian Product Information.".
• [20] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [21] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [22] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [23] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [24] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [25] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [26] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [27] DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
• [28] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [30] Multum Information Services, Inc. Expert Review Panel.
• [31] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [32] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [33] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [34] Product Information. Seroquel (quetiapine). Zeneca Pharmaceuticals, Wilmington, DE.
• [35] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [36] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [37] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [38] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [39] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [40] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [41] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [42] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [43] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [44] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [45] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [46] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [47] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [48] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [49] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [50] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [51] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [52] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [53] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.